MRNA Stock Price Today (June 2026) — Moderna, Inc. Analysis & Key Metrics 2026-06-26
Moderna, Inc. (MRNA) is trading at $67.27, up 12.59% today (as of June 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $43.20 (-35.8% upside).
- Volatility remains elevated (73.31% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (2.60% YoY) alongside significant competitive pressures.
MRNA Stock Analysis: Key Metrics & Valuation (June 2026)
Concise, actionable data for investors
Moderna, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $14.98B
P/E Ratio
Forward P/E: -11.32
Revenue Growth
Year over Year
Analyst Target
+-35.8% upside potential
Key Investor Questions About MRNA
What investors need to know before buying
Based on current market data, MRNA presents a overbought technical setup with caution warranted fundamentals.
- Technicals say: Overbought (RSI 73.19)
- Fundamentals say: Caution warranted (high leverage concerns)
MRNA's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MRNA investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.30B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, MRNA stock traded between $22.28 and $59.55—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 73.31% annualized volatility and β=1.45, the stock exhibits high sensitivity to market moves—making MRNA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
S&P 500 ends lower; chips tumble and Moderna rallies
<body><p>STORY: U.S. stocks ended marginally lower on Friday, with the Dow and S&P 500 each shedding less than a tenth of a percent, and the Nasdaq losing about a quarter of a percent.</p><p>AI-related chip stocks suffered steep declines as some investors worry that the massive spending to build AI data centers may take too long to pay off.</p><p>Robert Conzo is CEO and managing director of The Wealth Alliance.</p><p>"The AI ship, although we love the technology, everyone loves the idea, it's like a cruise ship where the captain knows where they're going, the passengers don't know where this is going, passengers get nervous. The captain is the CEOs of these companies, putting billions and billions and billions of dollars of infrastructure into the AI. The market is the passengers saying, 'When are we going to be profitable here? At what point does profitability come to play?' Analysts are saying 2030, could be longer. And when prices go up, up, up, up higher, suddenly you start to question that value."</p><p>A report that OpenAI was considering delaying its public debut until next year also weighed on risk sentiment related to AI stocks.</p><p>:: Apple</p><p>Elsewhere in the market, shares of Apple rallied more than 3% and partly rebounded from a selloff a day earlier. The tech giant on Thursday raised iPad and MacBook prices, blaming soaring memory and storage chip costs.</p><p>:: Archive</p><p>Shares of ON Semiconductor tumbled almost 24% after the company agreed to acquire chip maker Synaptics in an all-stock deal valued at about $7 billion. Shares of Synaptics dipped more than 3.5%.</p><p>:: Moderna</p><p>On the flipside, shares of Moderna surged almost 13% to their highest level since 2024 after the drug developer hosted an investor event and showcased its pipeline.</p></body>
Moderna, Nvidia, Sandisk, Palantir, ON Semi, and More Stocks That Explain Today’s Market
FEATURE Stocks finished lower Friday as tech shares extended their recent slump and chip makers broadly declined. Investors continued to rotate out of AI momentum names and into lagging sectors. Separately, President Donald Trump threatened 100% tariffs on all goods from any country that follows through on digital services taxes on U.
US Equity Markets End Lower Amid Technology Stocks Sell-Off
US equity indexes were lower on Friday amid a sell-off in technology stocks and despite a decline in
Stocks Struggle After OpenAI IPO Blow: Stock Market Today
Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.
Trending: Netflix stock bounces back, Moderna surges post–investor day, ON Semi plummets
Yahoo Finance's Jared Blikre takes a closer look at some of Friday's trending tickers and stories, including Moderna (MRNA), Netflix (NFLX), and ON Semiconductor (ON).
Moderna Shares Up on New Research Efforts for Autoimmune Disorder
Moderna shares were up 13% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years.
Why Moderna Stock Is Soaring and Leading the S&P 500 Today
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
Lilly, J&J and AbbVie Hit New Highs
Lilly, AbbVie and J&J extend winning streaks.
3 Mid-Cap Stocks Walking a Fine Line
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Frequently Asked Questions
Common investor questions about Moderna, Inc.
Moderna, Inc. (MRNA) is currently trading at $67.27. The RSI (14-day) is at 73.2, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $43.20 implies 35.8% downside from current levels. Volatility is high at 73.3% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Moderna, Inc. (MRNA): The trailing P/E ratio is -8.26, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -11.32, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 3.60. Price-to-Sales is 12.00. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 20 analysts covering MRNA, the consensus price target is $43.20. This represents a 35.8% downside from the current price of $67.27. The range spans from a low target of $21.00 to a high target of $69.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Moderna, Inc. (MRNA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Moderna, Inc. (MRNA) investors include: 1. High volatility (73.3% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (17.9% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Moderna, Inc.'s (MRNA) current debt and financial health profile: Total debt stands at $1.30B. The debt-to-equity ratio is 17.52, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 2.41, indicating strong short-term liquidity. The quick ratio is 2.23. The company holds $5.21B in cash and equivalents. Free cash flow is negative at $-20,000,000, which could limit the company's ability to manage debt obligations.